### 1 Genomic epidemiology of SARS-CoV-2 in Sudan: A retrospective analysis 2020-2022

- **Authors:** Maureen W. Mburu<sup>1#</sup>, Arnold W. Lambisia<sup>1#</sup>, Musab Elnegoumi <sup>2#</sup>, Eman O. M. 2
- Nour<sup>2</sup>, Osama M. M. Khair<sup>3</sup>, Elamin Abualas<sup>2</sup>, Rehab M Elhassan<sup>2</sup>, Muatsim A. M. Adam 3
- <sup>2</sup>, Khadija Said Mohammed<sup>1,12,13</sup>, John M. Morobe<sup>1</sup>, Leonard Ndwiga<sup>1</sup>, Edidah O. Moraa<sup>1</sup>, 4
- Timothy O. Makori<sup>1</sup>, Nickson Murunga<sup>1</sup>, Esther Nyadzua Katama<sup>1</sup>, Dorcas W. Waruguru<sup>4</sup>, 5
- Sarah Mwangi<sup>4</sup>, Sofonias K. Tessema <sup>4</sup>, Mawahib H. E. Adam <sup>2</sup>, Iman Mahmoud <sup>2</sup>, Hanan 6
- SalmanBabikir Mohamed <sup>2</sup>, Yousif A. A. Mustafa <sup>2</sup>, Mohamedtaha M. A. Mohamed <sup>2</sup>, 7
- Rasheeda H.A. Ahmed<sup>2</sup>, Nuha Y.I. Mohamed<sup>2</sup>, Rahma H. Ali<sup>2</sup>, Rasha S.M. Ebraheem<sup>2</sup>, Huda 8
- H.H. Ahmed<sup>2</sup>, Hamadelniel E. Abdalla<sup>2</sup>, Izdihar Mukhtar<sup>2</sup>, Abdalkhalig E. M. W. Alla<sup>2</sup>, Omer 9
- H. A. Elsheikh<sup>2</sup>, Abdualmoniem O. Musa<sup>5,7,8</sup>, Mahmoud Taha Faki<sup>5</sup>, Gada Mustfa Ahmed<sup>5</sup>, 10
- Thoyba E. R. Ahmed<sup>2</sup>, Mohammed A. O. Abdalla<sup>2</sup>, Mujtaba O. K. Mohamed<sup>2</sup>, Rayan A. A. 11
- Ahmed<sup>2</sup>, Samah M. M. AwadElkarim<sup>2</sup>, Basamat A. E. M. Ahmed<sup>2</sup>, Zainab A. I. Shumo<sup>2</sup>, 12
- Eiman N. A. Ahmed <sup>2</sup>, Samia S. A. Rushwan <sup>6</sup>, Phillip Bejon <sup>1</sup>, D. James Nokes <sup>1,9</sup>, Lynette 13
- Isabella Ochola-Oyier<sup>1</sup>, Charles N. Agoti<sup>1,10</sup>, George Githinji<sup>1,11\*</sup>, Shahinaz A. Bedri<sup>2</sup> 14

#### 16 **AFFILIATIONS:**

- <sup>1</sup> Kenya Medical Research Institute-Wellcome Trust Research Programme (KWTRP), Kilifi, 17
- 18 Kenya.

- <sup>2</sup> National Public Health Laboratory, Khartoum, Sudan. 19
- <sup>3</sup> Department of Molecular Biology, National University Biomedical Research Institute. 20
- <sup>4</sup> Africa Centre for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia. 21
- 22 <sup>5</sup> General Administration of Laboratories and Blood Banks, Ministry of Health, Kassala State,
- 23 Sudan.
- <sup>6</sup> Port Sudan Public Health Laboratory, Red Sea State, Sudan. 24
- <sup>7</sup> Microbiology Department, Faculty of Medicine and Health Sciences, Kassala University, 25
- 26 Sudan.
- 27 <sup>8</sup> Microbiology Department, Faculty of Medical Laboratory Sciences, Gezira University,
- Sudan. 28
- <sup>9</sup> School of Life Sciences and Zeeman Institute for Systems Biology and Infectious Disease 29
- 30 Epidemiology Research (SBIDER), University of Warwick, Coventry, UK.
- <sup>10</sup> Department of Public Health, Pwani University, Kilifi, Kenya. 31
- <sup>11</sup> Department of Biochemistry and Biotechnology, Pwani University, Kilifi, Kenya. 32
- <sup>12</sup>The Francis Crick Institute, London, UK.
  NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 33

<sup>13</sup> Division of Biosciences, Faculty of Life Sciences, University College London, London, UK. <sup>#</sup> Authors with equal contributions \* Corresponding author Corresponding: ggithinji@kemri-wellcome.org **Keywords:** Sudan, SARS-CoV-2, VOC, VOI and introduction Words: Abstract (202 words), Main text: (3932 words) 

Abstract

SARS-CoV-2 was first detected in Sudan on 13<sup>th</sup> March 2020. Here, we describe the genomic epidemiology of SARS-CoV-2 in Sudan between May 2020 and April 2022 to understand the introduction and transmission of SARS-CoV-2 variants in the country. A total of 667 SARS-CoV-2 positive samples were successfully sequenced using the nCoV-19 Artic protocol on the Oxford Nanopore Technology (≥70% genome completeness). The genomes were compared with a select contemporaneous global dataset to determine genetic relatedness and estimate import/export events. The genomes were classified into 37 Pango lineages within the **ancestral strain** (107 isolates across 13 Pango lineages), **Eta variant of interest (VOI)** (78 isolates in 1 lineage), **Alpha variant of concern (VOC)** (10 isolates in 2 lineages), **Beta VOC** (26 isolates in 1 lineage), **Delta VOC** (171 isolates across 8 lineages) and **Omicron VOC** (242 isolates across 12 lineages). We estimated a total of 144 introductions of the observed variants from different countries across the globe. Multiple introductions of the Eta VOI, Beta VOC and Omicron VOC were observed in Sudan mainly from Europe and Africa. These findings suggest a need for continuous genomic surveillance of SARS-CoV-2 to monitor their introduction and spread consequently inform public health measures to combat SARS-CoV-2 transmission.

## **INTRODUCTION**

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

The first confirmed SARS-CoV-2 case in Sudan was detected on 13th March 2020 and by end of April 2022 the country had confirmed a total of 62,131 cases and 4,933 COVID-19 related deaths [1]. A population-based study conducted between 1st March to 10th April 2021 in Omdurman city in Sudan estimated a seroprevalence of 54.6% with higher SARS-CoV-2 seropositivity among older people (>50 years)[2].

The first major SARS-CoV-2 wave of infections was observed between 7th April and 22nd September 2020 [1]. The government introduced various countermeasures such as closure of schools, airports and borders, restriction of movement across localities, dusk to dawn curfews and banning of religious and social gatherings in order to curb the spread of the virus, but these measures were relaxed from September 2020 [3]. Due to challenges in contact tracing earlier in the pandemic in Sudan, the SARS-COV-2 cases persisted and resulted in the second surge of infections between November 2020 and January 2021 [2] [3]. Notably, political instability in the country affected tracking and containment of SARS-CoV-2 infections. The third major wave was observed between December 2021 and February 2022 [1].

The major waves of SARS-CoV-2 cases observed in Sudan coincided with the infection waves observed in other African countries and these have been attributed to import/export events between different countries globally [4]. Sudan is bordered by seven countries namely, Eritrea, Ethiopia, South Sudan, Central African Republic, Chad, Libya, and Egypt with high movement across the borders and major cities lying either along the Red Sea or Nile River. Previously, transmission of viral infectious diseases such yellow fever and recurrent arbovirus outbreaks have attributed to rural-urban migration within the country[3]. However, the transmission dynamics of SARS-CoV-2 variants in Sudan and across its borders during the pandemic to date has not been previously described.

Genomic surveillance has been instrumental in monitoring and understanding SARS-CoV-2 variants evolution and spread in many countries globally [5]-[8]. This study aims to describe SARS-CoV-2 variants and transmission dynamics in Sudan using 667 whole genome sequences obtained from PCR-confirmed cases collected between May 2020 and April 2022.

**METHODS** 

94

95

100

105

106

113

114

- **Ethical approval**
- 96 The genomic surveillance protocol used at Kenya Medical Research Institute (KEMRI)
- Wellcome Trust (KWTRP) was reviewed and approved by the Scientific and Ethics Review 97
- 98 Committee (SERU) in KEMRI (SERU #4035). The SARS-CoV-2 positive samples were part
- 99 of the public health emergency response thus individual participant consent was waived.
- 101 SARS-CoV-2 sampling.
- 102 A total of 667 SARS-CoV-2 positive samples were sent to KWTRP-Kenya, ILRI-Kenya and
- South Africa for whole genome sequencing. The dates of collection spanned from 20<sup>th</sup> May 103
- 2020 to 18th April 2022. 104
  - Viral RNA extraction and cDNA synthesis
- SARS-CoV-2 samples were shipped from the National Public Health Laboratory Sudan to 107
- 108 KWTRP-Kenya (n=405). The samples shipped to KWTRP-Kenya were extracted using
- 109 OIAamp Viral RNA Mini kit (52906, Oiagen, Hilden, Germany) following the manufacturer's
- 110 instructions. SARS-CoV-2 positivity screening was done using various quantitative PCR kits.
- 111 Samples with a cycle threshold (Ct)  $\leq$  34 were selected for cDNA synthesis. 8µl of RNA was
- 112 reverse transcribed using 2 µl LunaScript® RT SuperMix Kit.
  - Whole genome amplification, library preparation and sequencing at KWTRP-Kenya
- 115 The SARS-CoV-2 genome was amplified using Q5® Hot Start High Fidelity 2X Master Mix
- (NEB, US) and the modified V4 ARTIC primers [9]. The amplicons were cleaned using 1x 116
- 117 AMPure XP beads (Beckman Coulter, US) as per the manufacturer's protocol, eluted in
- 118 nuclease free water and the eluent quantified using Qubit dsDNA HS Assay Kit (ThermoFisher
- 119 Scientific, US). Library preparation was performed as previously described [9], [10].
- End-prep was done using 50ng of PCR amplicons according to the ARTIC nCoV-2019 121
- 122 sequencing protocol v3 (LoCost) [11] using the NEBNext Ultra II End repair/dA-tailing Kit
- (NEB, US). Barcode ligation was done using the native barcoding expansion (EXP-NBD196) 123
- kit (Oxford Nanopore Technology, UK) and NEBNext Blunt/TA Ligase Master Mix (NEB, 124
- US). Thereafter, adaptor ligation was done using NEBNext Quick Ligation Module reagents 125
- 126 (NEB, US), Adaptor Mix II (ONT, UK) and 100ng of the barcoded sample following the

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

manufacturers instruction. The final loading concentration was normalised to 15ng and loaded on a SpotON R9 flow cell and sequenced on a GridION device [12]. SARS-CoV-2 genome assembly Basecalling and demultiplexing were executed simultaneously during sequencing using Guppy version 4.0.5 (https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html) with a minimum Q score of 1. Consensus SARS-CoV-2 genomes were generated using the ARTIC bioinformatics protocol (https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html). Briefly, the reads were filtered based on length (300-700bp) and mapped to the reference accession MN908947.3) genome (GenBank using Minimap2 (https://github.com/lh3/minimap2). Fast5 reads were used to polish the consensus genomes using Nanopolish (https://github.com/jts/nanopolish) and consensus genomes generated with a read depth of 20X. Additional Sudan data Additional sequences from Sudan generated at ILRI-Kenya (n= 199) and South Africa (n=204) available in the Global Initiative on Sharing All Influenza Data (GISAID) were also included in the subsequent analysis [13]. Lineage assignment, phylogenetics and mugration analysis The consensus genomes were assigned lineages using Pangolin version 4.0.6 [13]. Clade assignment and mutation profiling was done using NextClade v1.13.2 [14]. All sequences originating from Sudan were analysed against a global dataset of 13,122 SARS-CoV-2 genomes to ensure that global representation of sequences. The selected global subset had >95% genome coverage and were selected evenly from across the Pango lineage, time (month of collection) and continents. The genomes were collected from 1st September 2020 to 19th January 2022. All global reference genome sequences and associated metadata in this dataset are published in GISAID's EpiCoV database <a href="https://doi.org/10.55876/gis8.220815ga">https://doi.org/10.55876/gis8.220815ga</a>. The sequences from Sudan and the global dataset were aligned using Nextalign version 1.4.1 (https://github.com/neherlab/nextalign) against the SARS-CoV-2 reference genome. A likelihood (ML) tree was generated using IOTREE version 2.1.3 maximum (http://www.iqtree.org/) and a branch support was assessed using 1000 bootstrap iterations.

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180


181

182

The ML trees were converted to time resolved phylogenetic trees using TreeTime (https://github.com/neherlab/treetime). A Python script was used to estimate SARS-CoV-2 import and export events in Sudan based on the origin of sequence and time resolved tree's tips and internal nodes. The import/export events were visualized using R packages alluvial and tidyverse [15] **RESULTS Baseline demographic characteristics** A total of 667 SARS-CoV-2 samples were collected from 11 different locations in Sudan and a majority of these samples were from Khartoum (n=390, 58.5%), Kassala (n=180, 27%) and Port Sudan (n=66, 9.9%). Among this population, the median age was 40 years. Out of the 667 cases, 237 (35.5%) were presented with symptoms and only 4 (0.6%) had known international travel history. Metadata for variables such as vaccination status, travel history, sex, age, and reason for testing was lacking for >10% of the cases (Supplementary table 1). SARS-CoV-2 variants surveillance in Sudan Genomic surveillance of SARS-CoV-2 started in May 2020 in Sudan and the 667 genomes sequenced were classified into multiple variants namely, non-variant of concern/ non-variant of internet (non-VOC/non-VOI (n=140), Eta (n=78), Alpha (n=10), Beta (n=26), Delta (n=171) and Omicron (n=242) (**Figure1C**).

perpetuity.

It is made available under a CC-BY 4.0 International license.



**Figure 1: (A)** Stringency index showing the government intervention levels. **(B)** A weekly rolling average of the daily confirmed SARS-CoV-2 cases in Sudan as populated in <a href="https://ourworldindata.org/coronavirus/country/sudan">https://ourworldindata.org/coronavirus/country/sudan</a>. **(C)** Temporal distribution of detected SARS-CoV-2 variants.

The predominant lineages within the non-VOC/non-VOI group were A.29 (n=43, 30.7%), A (n=42, 30.0%) and B.1 (n=29, 20.7%). These lineages persisted through the first two major waves of SARS-CoV-2 infections in Sudan (**Figure 2**). The Eta VOI (B.1.525) was first observed in December 2020 and was sustained until August 2021 with the peak cases seen in

perpetuity.

It is made available under a CC-BY 4.0 International license .

March 2021 (**Figure 2**). Alpha and Beta VOC cases were seen to cocirculate between March 2021 and May 2021.

Nine Delta VOC lineages were observed between December 2020 and February 2022. The most predominant lineage across this period was B.1.617.2 (n=156, 91.2%). The other Delta VOC lineages were observed between October 2021 and February 2022 (**Figure 2**). By July 2021, the Delta VOC was the predominant SARS-CoV-2 variant in circulation in Sudan and become dominant by August 2021.

Twelve lineages within the Omicron VOC were observed in between January and April 2022 during the third major wave in Sudan (**Figure 2**). The most common Omicron lineages were BA.1.1 (n=87, 36.0%), BA.1 (n=60, 24.8%), BA.2 (n=49, 20.2%), and BA.1.1.14 (n=28, 11.6%).




Figure 2: Temporal distribution of detected SARS-CoV-2 lineages in Sudan between May 2020 to April 2022. The colours show the different VOCs/VOI, and the circle sizes indicate the frequency.

# Genetic diversity of SARS-CoV-2 in Sudan

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

Multiple clusters and singletons from the Sudan genomes were observed with each of the detected variants. The Sudan genomes were interspersed within the global datasets among all the variants (Figure 3).




Figure 3: Maximum likelihood phylogenetic trees of SARS-CoV-2 sequences from different lineages (A) non-VOC/non-VOI (B) Eta VOI (C) Alpha VOC (D) Beta VOC (E) Delta VOC, and (F) Omicron VOC from Sudan (coloured dots) and sub-sampled global sequences.

## Importations of SARS-CoV-2 variants in Sudan

Virus importation events into Sudan were estimated from the time-resolved phylogenetic trees. A total of 144 virus introduction events were estimated for all the variants from different parts of the globe. The introduction events for each variant were as follows: non-VOC/non-VOI (n=13), Alpha (n=7), Beta (n=11), Delta (n=24), Eta (n=13) and Omicron (n=76) (Supplementary figure 1).

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

**DISCUSSION** This study describes the genomic epidemiology of SARS-CoV-2 in Sudan between September 2020 and January 2022. Over this period, 37 lineages which were either non-VOCs/non-VOIs Alpha VOC, Eta VOI, Beta VOC, Delta VOC or Omicron VOC were in circulation in Sudan. These SARS-CoV-2 variants sustained the cases throughout 2021 until the third major wave driven by Omicron VOC in January 2022. The third wave coincided with both the relaxation of the stringency measures in Sudan and the introduction of Omicron, with its increased transmissibility and infectivity compared to other VOCs such as Delta and Beta [16], [17]. Lineage A.29 was first detected in Gambia in August 2020 and then spread with minimal infectivity and severity globally [18]. The lineage was first detected in Sudan in September 2020 and was sustained until February 2021 based on additional sequences deposited on GISAID [19]. Alpha VOC, Eta VOI, Beta VOC, and Delta VOC were detected and were in circulation between February 2021 and July 2021. However, no major waves were observed in Sudan coincidented with the introduction of these variants, which contrasts the association of these variants with surges of cases seen in other countries within Africa [6]. The common Omicron lineages detected in cocirculation in Sudan were BA.1.1 (30.7%), BA.1 (27.3%) and BA.2 (23.9%) and the frequency of these variants increased rapidly across the weeks in January 2022. Similar findings in transition of lineages and these omicron subvariants causing surges in cases have been reported elsewhere [20]–[23]. Our phylogenetic analysis showed the sequences from Sudan were interspersed within the global tree, suggesting the frequent global spread of the detected variants due to the movement of people across different countries. Multiple introductions of the Eta VOI, Beta VOC and Omicron VOC were observed into Sudan, mainly from Europe and Africa. Import/export events of the virus within Africa and across Europe have been previously described [6], [8]. Interestingly, only one Delta lineage B.1.617.2 was identified in Sudan and the phylogeny suggests a single introduction event that led further spread of Delta in Sudan through local transmission. However, this conclusion may be influenced by the limited sampling, especially lack of sampling between August and December 2021 following the replacement of the Delta. Our study had some limitations. First, the samples used in this analysis are only from two major cities: Khartoum; and Port Sudan, and we do not have detailed epidemiological data. Additionally, there is a lack of continuous sampling over time, making it difficult to draw solid conclusions on the complete diversity of SARS-CoV-2 in Sudan during the pandemic.

263

264

265

266

267

268

269

In conclusion, this study reveals the genetic diversity of SARS-CoV-2 variants in circulation in after multiple introductions of these variants in the country. These findings show that continuous genomic surveillance is key in monitoring and understanding the introduction and spread of SARS-CoV-2 variants within countries as it helps in upholding measures public health measures that can mitigate the spread of the virus.

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

**ACKNOWLEDGMENTS** We thank the Sudan Ministry of Health, Public Health Laboratory, Africa-CDC for facilitating sharing of sequenced SARS-CoV-2 samples. We would like to thank all the laboratories that have shared SARS-CoV-2 sequence data in GISAID that we included as comparison data in our analysis. **Funding Information** This works was supported by the National Institute for Health and Care Research (NIHR) (project references 17/63/82 and 16/136/33) using UK aid from the UK Government to support global health research, The UK Foreign, Commonwealth and Development Office and Wellcome Trust (grant# 220985/Z/20/Z) The views expressed in this publication are those of the author (s) and not necessarily those of NIHR or the Department of Health and Social Care, Foreign Commonwealth and Development Office. This work was also supported by the Sudan Public Health Laboratory (Public Health Authority), Africa-CDC, WHO-Afro, ASLM, and WHO-Kenya offices. **Data Availability Statement:** The Sudan daily case data for the study period was obtained and is freely available from the Our World in Data database. All genome sequences and associated metadata in this dataset are published in GISAID's EpiCoV database https://doi.org/10.55876/gis8.231110pw. The epidemiological data is available on the Virus Epidemiology and Control (VEC) Dataverse (DOI: https://doi.org/10.7910/DVN/782VRG). Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

**Conflicts of Interest:** The authors have declared no competing interest.

### **REFERENCES**

- 296 W. Moser et al., "SARS-CoV-2 Antibody Prevalence and Population-Based Death [2]
- 297 Rates, Greater Omdurman, Sudan," Emerg. Infect. Dis., vol. 28, no. 5, pp. 1026–1030,
- 2022, doi: 10.3201/eid2805.211951. 298
- 299 M. M. Mukhtar and M. Khogali, "The accelerating COVID-19 epidemic in Sudan," [3]
- Nat. Immunol., vol. 22, no. 7, pp. 2021, doi: 10.1038/s41590-021-00950-0. 300
- 301 [5] X. Deng et al., "Genomic surveillance reveals multiple introductions of SARS-CoV-2
- into Northern California," Science (80-.)., vol. 369, no. 6503, pp. 582-587, 2020, doi: 302
- 303 10.1126/science.abb9263.
- H. Tegally et al., "The evolving SARS-CoV-2 epidemic in Africa: Insights from 304 [6]
- 305 rapidly expanding genomic surveillance
- Z. Chen et al., "Global landscape of SARS-CoV-2 genomic surveillance and data 306 [7]
- sharing," Nat. Genet., vol. 54, no. 4, pp. 499-507, 2022, doi: 10.1038/s41588-022-307
- 01033-y. 308
- E. Wilkinson et al., "A year of genomic surveillance reveals how the SARS-CoV-2 309 [8]
- 310 pandemic unfolded in Africa," Science (80-.)., vol. 374, no. 6566, pp. 2021, doi:
- 10.1126/science.abj4336. 311
- 312 [9] A. W. Lambisia et al., "Optimization of the SARS-CoV-2 ARTIC Network V4
- Primers and Whole Genome Sequencing Protocol," Front. Med., vol. 9, no. February, 313
- pp. 2022, doi: 10.3389/fmed.2022.836728. 314
- G. Githinji et al., "Tracking the introduction and spread of SARS-CoV-2 in coastal 315
- 316 Kenya," Nat. Commun., vol. 12, no. 1, p. 4809, Dec. 2021, doi: 10.1038/s41467-021-
- 317 25137-x.
- 318 J. Quick, "nCoV-2019 sequencing protocol v3 (LoCost) V.3," 2020. [11]
- J. R. Tyson et al., "Improvements to the ARTIC multiplex PCR method for SARS-319 [12]
- 320 CoV-2 genome sequencing using nanopore.," bioRxiv Prepr. Serv. Biol., 2020, doi:
- 10.1101/2020.09.04.283077. 321
- A. Rambaut et al., "A dynamic nomenclature proposal for SARS-CoV-2 lineages to 322 [13]
- assist genomic epidemiology," Nat. Microbiol., vol. 5, no. 11, pp. 1403–1407, 2020, 323
- 324 doi: 10.1038/s41564-020-0770-5.
- J. Hadfield et al., "NextStrain: Real-time tracking of pathogen evolution," 325 [14]
- Bioinformatics, vol. 34, no. 23, pp. 4121–4123, 2018, doi: 326
- 327 10.1093/bioinformatics/bty407.
- R. C. R Core Team, "R: A Language and Environment for Statistical Computing," 328

329 Vienna, Austria, 2018. D. Ao et al., "SARS-CoV-2 Omicron variant: Immune escape and vaccine [16] 330 331 development," MedComm, vol. 3, no. 1. pp. doi: 10.1002/mco2.126. J. Chen, R. Wang, N. B. Gilby, and G. W. Wei, "Omicron Variant (B.1.1.529): 332 [17] 333 Infectivity, Vaccine Breakthrough, and Antibody Resistance," J. Chem. Inf. Model., vol. 62, no. 2, pp. 412–422, 2022, doi: 10.1021/acs.jcim.1c01451. 334 335 [18] and A. R. Áine O'Toole, Emily Scher, "Pango Lineages: Latest epidemiological lineages of SARS-CoV-2," 2022. 336 Y. Shu and J. McCauley, "GISAID: Global initiative on sharing all influenza data – 337 [19] from vision to reality," Eurosurveillance, vol. 22, no. 13, pp. 2017, doi: 338 10.2807/1560-7917.ES.2017.22.13.30494. 339 P. Elliott et al., "Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in 340 [20] England," Science (80-.)., vol. 376, no. 6600, 2022, doi: 10.1126/science.abq4411. 341 [21] O. Eales et al., "The new normal? Dynamics and scale of the SARS-CoV-2 variant 342 Omicron epidemic in England," medRxiv, p. 2022.03.29.22273042, 2022, doi: 343 344 10.1038/s41467-022-32096-4. NGS-SA, "Network for Genomic Surveillance in South Africa (NGS-SA) SARS-CoV-345 [22] 346 2 sequencing update." 347